USFDA shooting up warning letters to marketers for Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)

Center for Drug Evaluation and Research (CDER), of United States Food and Drug Administration have busy time in monitoring illogical claims made by the marketers and manufacturers. CDER recently shoots up lot of warning letters which are related to misappropriate claims like products are efficacious for the Coronavirus Disease 2019 (COVID-19). On 6th of March, USFDA has posted 7 COVID-19 related warning letters. Fabricated claims made by manufacturer and marketers in their websites, brand portals and social media platform are monitored by the USFDA. Many cases it is observed that the claims on your websites that establish the intended use of your products and misleadingly represent them as safe and/or effective for the treatment or prevention of COVID-19.

Here is the few of the recent waning letter issued for COVID-19 related irrational claim

Once COVID-19 become a global outbreak, and more and more healthcare, pharmaceuticals, food companies are involving unrealistic claim that their products are found to be efficacious against COVID-19. USFDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people.

It is advisable that companies should review websites, product labels, and other labeling and promotional materials to ensure that you are not representing products for a COVID-19 related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act.

Learn about USFDA warning letter and 483 observations >> How to handle 483 observations and USFDA warning letter >> Learn here